The FDA said it found traces of a known carcinogen in Zantac and its generic equivalents. CVS Health Corp said on Saturday it will discontinue sales the popular Zantac heartburn treatment and its own generic ranitidine products from its pharmacies after traces of a known carcinogen were found in some of the products by the U.S. Food and Drug Administration. The FDA said earlier this month that some of the pills contained small amounts of N-nitrosodimethylamine (NDMA), which has also been found in some widely used blood pressure medicines, leading to shortages of those drugs. read more https://www.huffpost.com/entry/cvs-zantac-ranitidine-suspension_n_5d91afa8e4b0019647ab056e
It's been a while since your post, but I wanted to offer some insight. It's concerning to hear about the discovery of a carcinogen in Zantac and its generic versions.
This underscores the importance of stringent safety regulations and thorough testing of pharmaceutical products. It's commendable that CVS Health Corp is taking proactive steps to discontinue sales of these products to ensure consumer safety. This incident highlights the need for greater transparency and oversight in the pharmaceutical industry to prevent such risks to public health. If you or someone you know is struggling with drug-related health issues, resources like the Texas Substance Abuse & Drug Addiction Hotlines can provide support and guidance.
